AVE Science&Technology CO.,LTD researches, (688067) Fair Value & Analysis
Healthcare · CN · Market cap 1.5B CNY
Fair value as of: Jun 24, 2026
Analysis
AVE Science&Technology CO.,LTD researches, (688067) currently trades at ¥21.58, while our model-based Fair Value estimate is ¥9.36 — implying the stock looks roughly 56.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
About the company
AVE Science&Technology CO.,LTD researches, develops, manufactures, markets, and services medical devices, biological reagents, remote medical diagnosis network, computer software, automatic control devices, and medical auxiliary equipment China, Europe, the United States, Asia, Africa, and internationally. The company offers urine formed elements analyzer and related reagents, automatic urine analyzers, multi-function microscopy analyzers, semi-automatic biochemical analyzers, feces analyzers, and vaginal secretions analyzers; and reagents and consumables comprising reagent packs, test strips, urine analyzer cleansers, urine sample collectors, and urine formed elements analyzer's quality control products. The company was incorporated in 2000 and is headquartered in Changsha, China.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is AVE Science&Technology CO.,LTD researches, (688067) undervalued?
What is the fair value of 688067?
What is the quality score of 688067?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.